# Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

> **NCT02240238** · PHASE1,PHASE2 · COMPLETED · sponsor: **NanoCarrier Co., Ltd.** · enrollment: 119 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** NC-6004
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02240238
- **Lead sponsor:** NanoCarrier Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2019-05-06
- **Final completion:** 2019-05-06
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02240238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02240238, "Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02240238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*